Bella Smith's show

CAR-T technology

0 0 hace 2 años
Chimeric antigen receptor (CAR)-engineered T cell therapy has been the most promising approach up to date. The main advantage of CAR-T cell is that it bypasses MHC restriction, which allows for direct activation of effector cells for the treatment of various types of tumors.
To fully validate the technology, which is different from CAR-T technology, the trial is intended to recruit approximately 330 patients and statistical results are expected to be released in 2023. Leading researcher ... Más informaciones

Síguenos en Facebook